Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
June 11, 2020•Clinical trial to enroll 144 patients total with expansion to additional sites
HOUSTON, June 11, 2020 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that Houston Methodist Hospital is...
-
June 8, 2020•Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19
GENEVA and RADNOR, Pa., June 08, 2020 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that the Phase 2/3 clinical...
-
June 1, 2020•First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100
MIAMI, June 01, 2020 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) (Relief) and its U.S. partner, NeuroRx, Inc. today announced treatment of the first patients with RLF-100 at the...
-
May 14, 2020•Study to enroll 144 patients with COVID-19 who have progressed to Acute Respiratory Distress and require intensive care with mechanical ventilation
GENEVA and RADNOR, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) (Relief) and its U.S. partner, NeuroRx, Inc. announced today that NeuroRx has completed final...
-
March 26, 2020Aviptadil is a patented synthetic form of Vasoactive Intestinal Polypeptide that has previously shown promise in treating ARDS
RELIEF THERAPEUTICS Holding AG (SIX: RLF) "Relief", together with NeuroRx, a Delaware Corporation. have filed an Investigational New Drug (IND) Application with the US FDA for a phase 2 trial of...
Click here to view our corporate presentation or on the image below
![]() |